<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To study the different therapy for different types of <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) in China </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Among 102 UC patients, 42 <z:hpo ids='HP_0011010'>chronic</z:hpo> relapse type UC patients were randomly divided into olsalazine <z:chebi fb="199" ids="26708">sodium</z:chebi> treatment group (n=21) and SASP group (n=21) </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical effects and safety were observed in the 2 groups </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-two first episode type UC patients were randomly divided into Heartleaf houttuynia herb treatment group (n=21) and SASP group (n=21) </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical effects were observed in the 2 groups while ultrastructure of colonic mucosa, ICAM-1 and the pressure of distant colon were studied in Heartleaf houttuynia herb group </plain></SENT>
<SENT sid="5" pm="."><plain>Eighteen patients (8 males, 10 females) with refractory UC and unresponsive to high-dose <z:chebi fb="2" ids="8378">prednisolone</z:chebi> and <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi> therapy more than one month were treated with Kangshuanling (7200 U/d) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="2" ids="8378">Prednisolone</z:chebi> was gradually stopped and <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi> was maintained </plain></SENT>
<SENT sid="7" pm="."><plain>Stool frequency, <z:hpo ids='HP_0002573'>rectal bleeding</z:hpo>, colonoscopy, general well-being, histology were observed and CD62p, CD63, CD54, Pgp-170 (flow cytometry), <z:chebi fb="0" ids="15627">TXA2</z:chebi> (RIA), blood platelet aggregation rate and <z:mp ids='MP_0005048'>thrombosis</z:mp> length in vitro were assessed </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: In the 42 <z:hpo ids='HP_0011010'>chronic</z:hpo> relapse type UC patients, the overall clinical effects of olsalazine <z:chebi fb="199" ids="26708">sodium</z:chebi> group (complete remission in 16, improvement in 4, inefficiency in 1) were better than those of SASP group (complete remission in 10, improvement in 4, inefficiency in 7, P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Symptomatic remission of olsalazine <z:chebi fb="199" ids="26708">sodium</z:chebi> group (complete remission in 15, partial remission in 5, inefficiency in 1) was better than that of SASP group (complete remission in 10, partial remission in 5, inefficiency in 6, P&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>The colonoscopic remission of olsalazine <z:chebi fb="199" ids="26708">sodium</z:chebi> group(complete remission in 11, partial remission in 9, inefficiency in 1) was better than that of SASP group (complete remission in 7, partial remission in 8, inefficiency in 6, P&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>The histologic remission of olsalazine <z:chebi fb="199" ids="26708">sodium</z:chebi> group (complete remission in 13, partial remission in 7, inefficiency in in 1) was better than that of SASP group (complete remission in 6, partial remission in 10, inefficiency in 5, P&lt;0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>The side effects of gastrointestinal tract in olsalazine <z:chebi fb="199" ids="26708">sodium</z:chebi> group were less than those of SASP group except for frequency of watery <z:hpo ids='HP_0002014'>diarrhea</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>No other side effects were observed in olsalazine <z:chebi fb="199" ids="26708">sodium</z:chebi> group while ALT increase, WBC decrease and <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">skin eruption</z:e> were observed in SASP group </plain></SENT>
<SENT sid="14" pm="."><plain>Two patients relapsed in olsalazine <z:chebi fb="199" ids="26708">sodium</z:chebi> group while 8 cases relapsed in SASP group during the flow-up period (from six months to one year) </plain></SENT>
<SENT sid="15" pm="."><plain>In the 42 first episode type UC patients, the clinical effect of Heartleaf houttuynia herb group (complete remission in 20, 95.2%; improvement in 1, 4.8%) was better than that of SASP group (complete remission in 15, 72.4%, improvement in 5, 23.8%; inefficiency in 1, 3.8%, P&lt;0.01) </plain></SENT>
<SENT sid="16" pm="."><plain>The time of stool frequency recovering to <z:mpath ids='MPATH_458'>normal</z:mpath> (5.6+/-3.3 d), and blood stool disappearance (6.7+/-3.8 d) and <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> disappearance (6.1+/-3.5 d) in Heartleaf houttuynia herb group was <z:hpo ids='HP_0000001'>all</z:hpo> shorter than that in SASP group (9.5+/-4.9 d, 11.7+/-6.1 d, 10.6+/-5.3 d, P&lt;0.01) </plain></SENT>
<SENT sid="17" pm="."><plain>Heartleaf houttuynia herb could inhibit the epithelial cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of colonic mucous membrane and the expression of ICAM-1 (45.8+/-5.7% vs 30.7+/-4.1%, P&lt;0.05) </plain></SENT>
<SENT sid="18" pm="."><plain>Compared with <z:mpath ids='MPATH_458'>normal</z:mpath> persons, the mean promotive speed of contraction wave stepped up (4.6+/-1.6 cm/min vs 3.2+/-1.8 cm/min, P&lt;0.05) and the mean amplitude of the wave decreased (14.2+/-9.3 kPa vs 18.4+/-8.0 kPa, P&lt;0.05) in active UC patients </plain></SENT>
<SENT sid="19" pm="."><plain>After treatment with Heartleaf houttuynia herb, these 2 indexes improved significantly (17.3+/-8.3 kPa, 3.7+/-1.7 cm/min, P&lt;0.05) </plain></SENT>
<SENT sid="20" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> persons, the postprandial pressure of sigmoid (2.9 +/-0.9 kPa) was higher than that of descending colon (2.0+/-0.7 kPa) and splenic flexure (1.7+/-0.6 kPa), while the colonic pressure (1.5+/-0.5 kPa, 1.4+/-0.6 kPa, 1.3+/-0.6 kPa) decreased significantly (P&lt;0.05) in active UC patients </plain></SENT>
<SENT sid="21" pm="."><plain>After treatment with Heartleaf houttuynia herb, the colonic pressure (2.6+/-0.8 kPa, 1.8+/-0.6 kPa, 1.6+/-0.5 kPa) recovered to <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="22" pm="."><plain>The pain threshold Heartleaf houttuynia herb, the colonic pressure (2.6+/-0.8 kPa, 1.8+/-0.6 kPa, 1.6+/-0.5 kPa) recovered to <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="23" pm="."><plain>The pain threshold of distant colon (67.3+/-18.9 mL) in active UC patients decreased significantly compared with that of <z:mpath ids='MPATH_458'>normal</z:mpath> persons (216.2+/-40.8 mL, P&lt;0.05) and recovered to <z:mpath ids='MPATH_458'>normal</z:mpath> after treatment with Heartleaf houttuynia herb(187.4+/-27.2 mL, P&lt;0.05) </plain></SENT>
<SENT sid="24" pm="."><plain>In the 18 refractory UC patients with platelet activation, after more than 4 wk of combined Kangshuanling and <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi> therapy, 16 patients achieved clinical remission, with a highly significant statistical difference (P&lt;0.01) between pre-and post-treatment mean scores for <z:hpo ids='HP_0000001'>all</z:hpo> disease parameters: stool frequency (8.2/d vs 1.6/d), <z:hpo ids='HP_0002573'>rectal bleeding</z:hpo> (score 2.7 vs 0.3), colonoscopy (score 2.6 vs 1.1), histology (score 12.0 vs 5.0), general well being (score 4.0 vs 0.6) and CD62p (8.0+/-3.1% vs 4.1+/-1.8%), CD63 (6.3+/-2.1% vs 3.2+/-1.6%), <z:chebi fb="0" ids="15627">TXA2</z:chebi> (548+/-85 ng/L vs 390+/-67 ng/L), platelet aggregation rate (43.2+/-10.7% vs 34.8+/-8.1%), <z:mp ids='MP_0005048'>thrombosis</z:mp> length in vitro (2.3+/-0.6 cm vs 1.8+/-0.3 cm), CD54 in blood (26.9+/-6.9% vs 14.4+/-5.1%), CD54 in tissues (51.1+/-6.2% vs 23.1+/-4.1%), Pgp-170 in blood (18.9+/-3.9% vs 10.4+/-2.7%), Pgp-170 in tissues (16.5+/-3.2% vs 10.2+/-2.3%, P&lt;0.01 or 0.05) </plain></SENT>
<SENT sid="25" pm="."><plain>CONCLUSION: Based on the characteristics of UC cases in China, different therapy should be given to different types of UC with expected satisfactory results </plain></SENT>
</text></document>